Close Menu
  • Home
  • News
  • Lifestyle
  • Law
  • Business
  • Education

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Ohio GOP Seeking to Change Voter-Approved Adult-Use Cannabis Law

May 30, 2025

U.S. Court of Appeals Rejects Legal Challenge Claiming Cannabis Prohibition is Unconstitutional

May 29, 2025

Montana Gov. Signs Bill Reserving $12M of Cannabis Tax Revenues for ‘Habitat Legacy Account’

May 28, 2025
Facebook X (Twitter) Instagram
Sunday, June 1
  • Home
  • Contact
  • Privacy Policy
  • Terms & Conditions
Facebook X (Twitter) Instagram LinkedIn VKontakte
Smoke Professional
  • Home
  • News

    More Than 1,000 Arrested in Sweep of U.K. Weed Grows

    July 8, 2023

    Scotland Calls On UK To End ‘Failed’ Drug War With Decriminalization And Harm Reduction Approach

    July 8, 2023

    Germany’s draft law for first phase of cannabis reform

    July 8, 2023

    High Times Cannabis Cup Illinois: People’s Choice Edition 2023 Kicks Off

    July 8, 2023

    Pennsylvania Committee Advances Expansion to State Medical Cannabis Program

    July 7, 2023
  • Lifestyle

    How Watching the News Can Trigger Anxiety and Panic Attacks

    October 28, 2024

    Record High Cannabis and Hallucinogen Use Among Adults

    October 27, 2024

    Weekend Sleep Catch-Up May Lower Heart Disease Risk by 20%

    October 27, 2024

    Energy Drinks Linked to Poor Sleep Quality and Insomnia

    October 26, 2024

    First Psychedelic Church for Magic Mushrooms

    October 26, 2024
  • Law

    Ohio GOP Seeking to Change Voter-Approved Adult-Use Cannabis Law

    May 30, 2025

    Federal Lawmakers Call for Medicaid Fraud Investigation Into Florida Anti-Cannabis Political Group

    May 26, 2025

    Minnesota Ends Criminal Penalties for Bong Water

    May 23, 2025

    Minnesota Bill to Set Up Adult-Use Cannabis Industry Moves to Governor

    May 22, 2025

    Pennsylvania House Passes Cannabis Legalization Bill

    May 8, 2025
  • Business

    U.S. Court of Appeals Rejects Legal Challenge Claiming Cannabis Prohibition is Unconstitutional

    May 29, 2025

    Montana Gov. Signs Bill Reserving $12M of Cannabis Tax Revenues for ‘Habitat Legacy Account’

    May 28, 2025

    Minnesota Tribe Signs Agreements to Open Adult-Use Dispensaries Off Tribal Land

    May 28, 2025

    Washington to Issue New Social Equity Cannabis Licenses This Summer

    May 27, 2025

    DEA Raid Confiscates Over 29,000 Cannabis Plants in New York

    May 26, 2025
  • Education

    CBD and the Aging Population—What Science Says Today

    March 12, 2025

    Wholesale Nootropic Skincare: Boost Your Product Line

    March 10, 2025

    Ideal for Your Business Needs

    March 8, 2025

    A Must-have For Every Smoke Shop

    March 3, 2025

    The Perfect Addition to Your Product Line

    March 1, 2025
Smoke Professional
You are at:Home»News»NICE recommends Epidyolex for tuberous sclerosis complex
News

NICE recommends Epidyolex for tuberous sclerosis complex

adminBy adminFebruary 18, 2023No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

The CBD-based drug, Epidyolex, will now be prescribed through the NHS for the treatment of seizures related to tuberous sclerosis complex (TSC).

From 1 March 2023, patients living with TSC will have access to the cannabinoid-based treatment, Epidyolex, through the NHS, following a new recommendation from the The National Institute for Health and Care Excellence (NICE).

According to an announcement from producer Jazz Pharmaceuticals on Tuesday 31 January, NICE has recommended the treatment be available for reimbursement by NHS England as an adjunctive therapy for seizures associated with TSC in patients two years of age and older.

TSC is a rare genetic condition, which is estimated to affect between 3,700 and 11,000 people in the UK and around 1 million people worldwide. It causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs. 

Epilepsy is one of the most common neurological features and can severely impact the lives of patients, with conventional treatments unable to control seizures in up to half of cases. 

While TSC can be diagnosed in infancy, many children are not diagnosed until later in childhood when seizures begin and other symptoms appear.

Epidyolex, which contains an isolated form of CBD, has now been approved for use in the UK in three rare forms of epilepsy. It has been prescribed through the NHS since 2019 for seizures associated with Lennox Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. 

In August 2021 it was approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for use as an adjunctive treatment of seizures associated with TSC. The Scottish Medicines Consortium, Northern Ireland’s Strategic Planning and Performance Group and the All Wales Medicines Strategy Group have all previously approved the drug for use in the condition.

Dr Pooja Takhar, joint chief executive at Tuberous Sclerosis Association (TSA), said: “The TSA is delighted with this decision, along with people living with TSC and their families. TSC is a very difficult to manage condition, with common issues including epilepsy in eight out of 10 people.

“Up to half of the people with TSC-related epilepsy are unable to manage their seizures with standard anti-seizure medication, leading to a massive unmet need for new treatment options. This underlines why we are so pleased that this medicine will now be available on the NHS in England, improving lives in the TSC community.”

Epidyolex was developed by GW Pharmaceuticals and is one of just three licensed cannabis medicines in the UK. GW Pharma was acquired by Jazz Pharmaceuticals in May 2021 for $7.2 billion.

Simon Newton, general manager at Jazz Pharmaceuticals, commented: “We welcome NICE’s recommendation which provides appropriate patients across the UK, who are living with TSC, a difficult to treat condition, access to a new treatment option. This is an important milestone not only for those living with TSC but also for their families, carers and clinicians. 

“This demonstrates the importance of randomised clinical trials (RCTs) and regulatory approval in providing reimbursed access to cannabinoid-based medicines to patients who may benefit.”

A number of children with treatment-resistant epilepsy are prescribed unlicensed cannabis medicines privately in the UK, however regulators say more RCTs are needed before these can be approved for use through the NHS.

Last year NHS England and the National Institute for Health Research (NIHR) were said to be ‘working closely’ on two RCTs to compare the effects of medicines containing CBD, and CBD with THC, and a placebo. These were expected to begin in 2023 but further information is yet to be released.

NHS director of Specialised Commissioning and interim director of Commercial Medicines, John Stewart, said: “It is great news for patients that the NHS is able to offer this latest licensed cannabis treatment, which in this instance can help reduce the seizure frequency for those living with a serious genetic condition and significantly improve their quality of life.

“The NHS is committed to making innovative treatments available to patients as quickly as possible, at a fair price to taxpayers, following regulatory approval that provides patients with the knowledge that new treatments are safe and manufactured in a quality controlled environment.”

Home » News » NICE recommends Epidyolex for treatment of tuberous sclerosis complex

Source link

Complex Epidyolex NICE Recommends sclerosis tuberous
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleVegas Weed Advocates Call for Easing of Distance Buffers for Cannabis Businesses
Next Article What is Ketamine: The Musical? 
admin
  • Website

Related Posts

New Study Reviews Inequity in Cannabis Research, Recommends How To Move Forward

December 18, 2023

Very Nice People | High Times

October 13, 2023

NCAA Committee Recommends Removing Cannabis from Banned Substances List

September 25, 2023

Comments are closed.

Our Picks

Ohio GOP Seeking to Change Voter-Approved Adult-Use Cannabis Law

May 30, 2025

U.S. Court of Appeals Rejects Legal Challenge Claiming Cannabis Prohibition is Unconstitutional

May 29, 2025

Montana Gov. Signs Bill Reserving $12M of Cannabis Tax Revenues for ‘Habitat Legacy Account’

May 28, 2025

Minnesota Tribe Signs Agreements to Open Adult-Use Dispensaries Off Tribal Land

May 28, 2025
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
Don't Miss
Law

Ohio GOP Seeking to Change Voter-Approved Adult-Use Cannabis Law

By adminMay 30, 20250

Republican lawmakers in Ohio are seeking to make changes to the 2023 cannabis legalization law approved…

U.S. Court of Appeals Rejects Legal Challenge Claiming Cannabis Prohibition is Unconstitutional

May 29, 2025

Montana Gov. Signs Bill Reserving $12M of Cannabis Tax Revenues for ‘Habitat Legacy Account’

May 28, 2025

Minnesota Tribe Signs Agreements to Open Adult-Use Dispensaries Off Tribal Land

May 28, 2025

Subscribe to Updates

Get the latest creative news from Smoke Unlimited about Weed & CBD vaping.

From Our Partners
About Us
About Us

Get all the current news stories, latest trends and legislation regarding cannabidiol, products, usages and its benefits. So don’t miss out any buzz and stay tuned! We offer a minute to minute updates regarding Marijuana industry.

Facebook X (Twitter) Instagram Pinterest
Our Picks

Ohio GOP Seeking to Change Voter-Approved Adult-Use Cannabis Law

May 30, 2025

U.S. Court of Appeals Rejects Legal Challenge Claiming Cannabis Prohibition is Unconstitutional

May 29, 2025

Montana Gov. Signs Bill Reserving $12M of Cannabis Tax Revenues for ‘Habitat Legacy Account’

May 28, 2025
Sponsors
Copyright © 2025. SmokeProfessional
  • Home
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.